Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension

Agnès Veyradier, MD; Toshiya Nishikubo, MD; Marc Humbert, MD; Martine Wolf, MD; Olivier Sitbon, MD; Géraud Simonneau, MD; Jean-Pierre Girma, PhD; Dominique Meyer, MD

**Background**—The presence of dysfunctional von Willebrand factor (vWF) in pulmonary arterial hypertension (PAH) was suggested to be related to increased proteolysis.

**Methods and Results**—In 10 patients with severe PAH, we studied the proteolysis of plasma vWF (vWF levels, multimeric distribution, proteolytic pattern, and cleaving protease activity) and hemodynamic variables (mean pulmonary artery pressure, cardiac index, and total pulmonary vascular resistance) at baseline and 30 days after initiation of continuous prostacyclin infusion. At baseline, vWF levels were significantly increased, vWF proteolysis was excessive, and vWF-cleaving protease activity remained normal. These biological abnormalities were reversible and paralleled the improvement of hemodynamics under vasodilator treatment with prostacyclin.

**Conclusions**—The excessive proteolysis of vWF in PAH is likely to be related to an increased susceptibility of vWF to proteases induced by high shear rates rather than to an enhanced release of enzymes. (*Circulation. 2000;102:2460–2462.*)

**Key Words:** hypertension, pulmonary ■ von Willebrand factor ■ proteins ■ prostaglandins

---

**Methods**

**Study Population**

Ten patients with severe PAH (1 man and 9 women, age 39.7 ± 10.4 years) were evaluated at baseline (D₀) and 30 days after initiation of continuous infusion of prostacyclin (D₃₀). Five patients had primary pulmonary hypertension and 5 had PAH secondary to fenfluramine derivatives (n = 3), a CREST (Calcinosis, Raynaud’s phenomenon, Esophageal dysfunction, Sclerodactyly, Telangiectasia) syndrome (n = 1), or Eisenmenger’s syndrome (n = 1). New York Heart Association functional class was III (n = 4) or IV (n = 6). Ten healthy volunteers (age 38.1 ± 10.2 years) were used as controls. All subjects were tested after appropriate consent had been obtained in accordance with the declaration of Helsinki.

**Biological Parameters**

Venous blood was collected onto 1/10 final volume of 3.8% sodium citrate and protease inhibitors (final concentrations: 5 mmol/L EDTA, 6 mmol/L N-ethylmaleimide, and 1 mmol/L leupeptin), and platelet-poor plasma was obtained as described previously. Factor VIII clotting activity (VIII:C), vWF antigen (vWF:Ag), ristocetin cofactor activity (vWF:RCo), and vWF-cleaving protease activity were measured as described previously. Multimeric composition of plasma vWF was estimated by SDS-1% agarose gel electrophoresis. The relative percentage of the LMW multimers (∼5mers) was determined by densitometric analysis of the autoradiographs (Omnis Media Scanner XRS, Bio Image program, Millipore Co). vWF subunit and proteolytic degradation fragments were analyzed by SDS-5% PAGE under reducing conditions followed by immunoblotting with a polyclonal anti-reduced vWF antibody; the results were
expressed as the percent that each band contributed to the total in each lane. Each plasma sample was tested in triplicate.

**Hemodynamic Variables**
Mean pulmonary arterial pressure (mPAP), cardiac index (CI), and total pulmonary vascular resistance (TPVR) were obtained during right-side heart catheterization.

**Statistical Analysis**
Results from PAH patients (mean±SD) were compared with controls by a U-Mann Whitney test. The evolution within the PAH group was analyzed by Wilcoxon test. Significance was considered for \( P,0.05 \).

**Results**
In all PAH patients, hemodynamic variables (mPAP 75.0±12.8 mm Hg, CI 1.9±0.2 L/min·m\(^{-2}\), TPVR 39.1±5.1 IU/m\(^{-2}\) at \( D_0 \)) were significantly improved at \( D_{30} \) (mPAP 66.0±11.9 mm Hg, CI 2.1±0.3 L/min·m\(^{-2}\), TPVR 31.5±4.4 IU/m\(^{-2}\)) (\( P<0.04 \)).

At \( D_0 \), PAH patients exhibited a 2-fold increase of VIII:C and vWFAg levels (\( P<0.005 \), contrasting with a normal vWFRCo (Figure 1A). A loss of the HMW multimers of vWF was observed concomitantly with a 3-fold increase of the LMW multimers (Figure 1B and Figure 2A). In addition to the predominant 270-kDa subunit, 5 proteolytic fragments of vWF were present in both controls and PAH patients (Figure 2B), the latter demonstrating a similar 2-fold increase of all proteolytic fragments (\( P<0.005 \)) (Figure 1C). In contrast, vWF-cleaving protease activity was similar to controls (Figure 1D).

At \( D_{30} \), vWF-cleaving protease activity and vWFRCo remained normal, whereas VIII:C and vWFAg decreased to almost normal levels (\( P<0.02 \)) (Figure 1). The proportion of LMW multimers of vWF decreased concomitantly with a partial restoration of the HMW multimers (Figure 2A), and all proteolytic fragments decreased proportionally (Figure 2B).

**Discussion**
This study was focused on the features of vWF proteolysis in PAH and its evolution under prostacyclin infusion. Before treatment, enhanced vWF proteolysis was clearly demonstrated by both a rise in the proportion of its LMW multimers and an increase of its proteolytic fragments. In all patients, this excessive proteolysis was characterized by a 2-fold increase of the 5 proteolytic fragments present in controls, which suggests that it may be related to an enhanced physiological mechanism. This is at variance with the results of Lopes and Maeda,\(^7\) who detected only 4 proteolytic fragments and a more significant increase in the 176-kDa fragment, with, however, a variable proteolytic pattern between patients. The reason for this difference may be methodological, because we used native plasma instead of immunoabsorbed vWF and different anti-vWF antibodies. This increased proteolysis of vWF prompted us to analyze the role of its physiological specific cleaving protease, the activity of which was recently demonstrated to be decreased in thrombotic thrombocytopenic purpura,\(^4\,12\) a thrombotic microangiopathy characterized by the presence of ultralarge multimers of vWF. Surprisingly, in PAH patients, despite enhanced proteolysis of vWF, we failed to demonstrate an increased activity of vWF-cleaving protease.

Thus, the mechanisms for the excessive proteolysis of vWF in PAH remain questionable. In the current study, the absence of relevance of vWF-cleaving protease and the presence of physiological proteolytic fragments make unlikely the involvement of an enhanced release of enzymes. Therefore, an increased susceptibility of vWF to proteases may be suggested. The latter is known to be induced by structural modifications of vWF as hyposialylation\(^13\) and/or conformational changes induced by high shear stress.\(^14\) A very recent study\(^15\) showed that vWF was hyposialylated in PAH, but the evolution under prostacyclin was not analyzed. In the present
In the present study, prostacyclin therapy failed to normalize completely all the abnormalities of vWF, but evaluation was performed only after a 1-month prostacyclin treatment.

Of course, all the mechanisms reported to explain vWF dysfunction in PAH are not exclusive but instead are probably associated to support the cellular, biochemical, and hemodynamic abnormalities observed in PAH. Among these mechanisms, the present study underlines the role of an excessive proteolysis of vWF and provides new clues to explain its pathophysiology. The improvement of vWF under prostacyclin emphasizes both the cellular and hemodynamic effects of this drug. However, the relationships between the pulmonary vascular disease involving high shear rates and the endothelial perturbation as an initiating and/or exacerbating factor need further investigation to elucidate the complex pathogenesis of PAH.

Acknowledgments
We thank Bernadette Obert and Anne Houllier for expert technical assistance.

References
Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension

Agnès Veyradier, Toshiya Nishikubo, Marc Humbert, Martine Wolf, Olivier Sitbon, Gérald Simonneau, Jean-Pierre Girma and Dominique Meyer

_Circulation_. 2000;102:2460-2462
doi: 10.1161/01.CIR.102.20.2460

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2000 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/102/20/2460

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/